WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced that Mike Wilkinson, Ph.D., executive vice president and chief information officer, has been named to the 2016 PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
Published by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life sciences industry.
“I appreciate being recognized by PharmaVOICE and being included alongside this list of impressive industry leaders,” Dr. Wilkinson said. “This honor highlights the strengths and teamwork within PPD and among the team of technology, innovation and performance professionals I work with daily to provide industry-leading service for biopharmaceutical clients’ research programs.”
The honor recognizes Dr. Wilkinson’s ability to inspire and motivate colleagues, his influence as a corporate leader and his positive impact on the industry through his actions. A profile of Wilkinson appears in the annual PharmaVOICE 100 issue.
“Dr. Mike Wilkinson’s drive to embrace technological innovation to transform clinical trials, along with his skills at building success through inspired leadership, are just a few of the reasons why he is being honored as a PharmaVOICE 100,” said Taren Grom, editor of PharmaVOICE. “Dr. Wilkinson illustrates what it means to think bigger, do more, and lead with passion and integrity.”
Dr. Wilkinson joined PPD in 2008 as executive vice president of global clinical development, responsible for providing strategic leadership to PPD's Phase II-IV operations in North America; Latin America; Europe, Middle East and Africa; and Asia Pacific. Dr. Wilkinson spent more than two decades in the military, including service as a Navy SEAL, an aviation physiologist, White House liaison officer with Marine One Executive Transport, director of operations for the Joint Special Operations Medical Training Center and project director for the V-22 Osprey military aircraft.
Dr. Wilkinson earned a doctorate in physiological optics from Indiana University, a master's degree from Penn State University and a bachelor's degree from Ohio University.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 16,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Dr. Wilkinson and his selection for the 2016 PharmaVOICE 100 list contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.